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ABSTRACT
Site-selectiveadenosine(A)toinosine(I)RNAediting
by the ADAR enzymes has been found in a variety of
metazoan from fly to human. Here we describe a
method to detect novel site-selective A to I editing
thatcanbeusedonvarioustissuesaswellasspecies.
We have shown previously that there is a preference
for ADAR2-binding to selectively edited sites over
non-specific interactions with random sequences of
double-stranded RNA. The method utilizes immuno-
precipitation (IP) of intrinsic RNA–protein complexes
to extract substrates subjected to site-selective edit-
ing in vivo, in combination with microarray analyses
of the captured RNAs. We show that known single
sites of A to I editing can be detected after IP using
anantibodyagainsttheADAR2protein.TheRNAsub-
strates were verified by RT–PCR, RNase protection
and microarray. Using this method it is possible to
uniquely identify novel single sites of selective A to I
editing.
INTRODUCTION
Adenosine to inosine (A to I) RNA editing is known to change
the sequence of speciﬁc pre-mRNAs in metazoans from ﬂy
to human. ADAR2, a member of the ADAR (adenosine deam-
inase that acts on RNA) family, deaminates A to I selecti-
vely within double-stranded RNAs (dsRNAs) interrupted by
bulges, mismatches or loops [reviewed in (1)]. ADAR editing
with low selectivity can also occur on completely dsRNA.
This is a type of hyper-editing that has been found within
introns and untranslated regions (UTRs) of mRNAs, pre-
ferentially in repetitive Alu sequences (2–6). Only a few
site-selective ADAR substrates have been detected. In
mammals, most selectively edited sites targeted by ADARs
have been found in pre-mRNAs expressed in the central
nervous system. The most prominent sites of selective edit-
ing are in mRNA coding for several subunits of the AMPA
(a-amino-3-hydroxy-5-methyl-4-isoxazole) glutamate recep-
tor (GluR). Editing of subunit B (GluR-B) results in altered
receptor properties, changing receptor permeability to Ca
2+
and the ability to recover after desensitization (7–9). In
exon 11 the Q/R site is edited to nearly 100% giving rise
to a codon change from glutamine (Q) to arginine (R). In
exon 13 the edited R/G site causes an arginine (R) to glycine
(G) codon change that is developmentally regulated. The
dsRNA structure required for ADAR editing at these sites
is formed by an inverted repeat located in the downstream
intron [review by (10)]. Another prominent substrate for
site-selective A to I editing is the transcript of the serotonin
receptor 5-HT2C. Transcripts encoding the 2C receptor sub-
type undergoAtoIediting at5sites:A,B,C0,Cand Dsituated
in close proximity to each other (11). Editing alters the coding
potential of the second intracellular loop, reducing the efﬁci-
ency of the interaction between the receptor and the G protein.
Most of the selectively edited sites have been found fortuit-
ously as A to G changes when comparing cDNA with genomic
sequence, since inosine is seen as guanosine in the process of
reversetranscription.However,asigniﬁcantamountofinosine
has been found within the poly(A) fraction of cellular RNA in
mouse brain (12).
Co-immunoprecipitation is a powerful tool to precipitate-
speciﬁc protein complexes. Further, it has been widely used to
study RNA–protein interactions. One example is the identi-
ﬁcation of target RNA for the Nova protein in mouse brain
using an ultraviolet cross-linking and immunoprecipitation
assay (13). In another more general approach to identify
mRNA–protein complexes (mRNPs) called ribonomics,
RNA targets were detected using antibodies to RNA-
binding proteins followed by genomic arrays (14).
We have shown previously that ADAR binds more prefer-
entially to selectively edited sites than to random sequences of
dsRNA (15). Moreover, ADAR2 was shown to bind with a
similar afﬁnity to an editing substrate as to the product (16).
Based on this knowledge we have developed a method to ﬁnd
novel ADAR substrates by extracting intrinsic ADAR2–
RNA substrate complexes from mouse brain by co-
immunoprecipitations using an anti-ADAR2 antibody. The
speciﬁcity of this method has been veriﬁed by the detection
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doi:10.1093/nar/gni169of known site-selectively edited substrates using RT–PCR,
RNase protection and genomic microarray analyses. We pre-
sent a powerful method with the potential to ﬁnd novel sites of
selective editing in different tissues and organisms.
MATERIALS AND METHODS
Isolation of RNA–protein complex from mouse brain
Three mouse brains were homogenized in HBSS [1· Hank’s
solution (HBSS GIBCO no. 14185-045)] and 1 M HEPES
(pH 7.3) using a glass grinder. The suspension was washed
in cold 1· HBSS and the pellet was frozen in liquid nitrogen.
The pellet was resuspended in PXL [1· D-phosphate-buffered
solution (PBS) (GIBCO no. 14200-67), 0.1% SDS, 0.5%
deoxycholate and 0.5% NP-40] and ribonucleoside vanadyl
complex (Sigma) on ice. The suspension was sonicated and
treated with DNase I RQ1 (SIGMA). After centrifugation at
10000 g for 20 min, 4 C, the supernatant was used for
the immunoprecipitation (IP).
Immunoprecipitation of RNA–ADAR2 complexes
Anti-human ADAR2 antibody was made from recombinant
histidine tagged human ADAR2 (hADAR2) protein, kindly
provided by professor Brenda Bass’ laboratory. The
hADAR2 protein was concentrated using a centricon YM30
(Millipore) run out on 8% SDS–PAGE gel. The band cor-
responding to hADAR2 was excised and immunized four
times into rabbits (Agrisera; Umea ˚ Sweden). The serum
was checked for immuno-reactivity and supplemented with
0.05% sodium azide.
To reduce non-speciﬁc binding prior to use in IPs the
Sepharose A beads were incubated with tRNA (100 mg/ml)
and BSA (100 mg/ml) in 1· PBS, washed once in 1· PBS and
resuspended in 1 vol of 1· PBS and 0.05% NaN3. The cell
lysis extract from one mouse brain was pre-cleared with 50 ml
of Sepharose A stock for 30 min at 4 C with rotation. The pre-
cleared lysate was incubated with anti-ADAR2 polyclonal
antibody or pre-immune serum for 2 h at 4 C with rotation.
The lysate-antibody was mixed with 50 ml of prepared Sepha-
rose A stock and incubated for 1 h at 4 C with rotation. The
bead–antibody-lysate complex was rinsed three times in wash
buffer containing 1· PBS, MgCl2 (2 mM), EDTA (15 mM),
NP-40 (1%) and Tween-20 (0.5%) including 1 protease Inhib-
itor Cocktail tablet/10 ml buffer (Roche) and rinsed once in 1·
PBS, and eluted in 1· PBS plus 1% SDS at 65 C for 10 min.
Verification of ADAR2-binding using western blot
The IP eluate (10 ml) was boiled in SDS for 10 min prior to
fractionation by electrophoresis on a 4–15% pre-made SDS–
PAGE gel (BioRad) and transferred to a PVDF membrane by
electroblotting. Anti-hADAR2 was used as primary antibody
andanti-rabbit/HRP(DakoCytomation)wasusedassecondary
antibody. The blots were developed using Amershams ECL
plus Western Blotting Detection System and developed in a
LAS 1000 system (Fujiﬁlm).
Preparation of RNA after immunoprecipitation
The protein fraction was removed from the protein–RNA elu-
ate after the IP by adding 1.8 mg of proteinase K (Roche) and
incubated at 37 C for 15 min prior to a phenol/chloroform
extraction and precipitation. The RNA was puriﬁed using
RNeasy according to the manufacturer’s instruction (Qiagen).
Microarray preparation
Preparation of labeled cRNA from the immunoprecipitated
RNA was done according to Affymetrix Two-Cycle Target
Labeling Assay. Labeled cRNA from nine mouse brains
were hybridized to each Mouse Genome 430A 2.0 Array
(Affymetrix). Scanning was performed after adding
streptavidin-phycoerythrin Biotinylated anti-streptavidin anti-
body (SAPE) according to standard protocols Affymetrix Inc.
(Santa Clara, CA).
VerificationofknownADAR2substratesusingRT–PCR
The reverse transcription reactions were done with the
Sensiscript RT kit (Qiagen) using hexanucleotide mix
(Roche). A radioactive PCR using taq polymerase from
Qiagen was performed for 25 cycles. Primers mGluRB-R/
G-R (50-GGGGAGTTCTATATTCTACGGC-30), mGluRB-
Q/R-R (50-GACACCATGAATATCCACTTGAGACC-30)a n d
serotonin-R (50-GGCCTTAGTCCGCGAATTGAACCGGC-30)
were radioactively labeled by T4 polykinase (invitrogen) using
[g-
32P]ATP (NEN Perkin Elmer). The following non-radioactive
primers were also used in the different PCRs: mGluRB-R/G-F
(50-CCCACATTTCTGGCCCTTGTGCC-30), mGluRB-Q/R-F
(50-TTTGCCTACATTGGGGTCAGTG-30) and serotonin-F
(50-GTCCATCATGCACCTCTGCG-30). The result was shown
on a native 5% PAGE gel. As negative controls the acidic ribo-
somal protein P0 (ARPP P0) and GluR-A were ampliﬁed using
primers ARPP P0-F (50-GCACTGGAAGTCCAACTACTTC-
30), ARPP P0-R (50-TGAGGTCCTCCTTGGTGAACAC-30),
mGluRA-F (50-CCAGAGCTGGTGCTGGTCAGCTCTCG-30)
and mGluRA-R (50-GAAGTATATACGACCACTGTCATC-30).
All primers were labeled with [g-
32P]ATP as described above.
For sequencing the R/G site, primer mGluRB-R/G-seq (50-
GGGCCAGTTCTCAAACTTCTCTGGCCCC-30) was used.
Verification of known ADAR2 substrates using
RNase protection
The RNase protection assay was done using Ribonuclease
Protection Assay kit (RPA III no. 1414) from Ambion. Tem-
plate RNA was immunoprecipitated from ﬁve mouse brains.
To make the probe, the GluR-B was ampliﬁed by PCR using
the mGluRB-R/G-F and mGluRB-R/G-R primers on genomic
DNA from N2 cells, and the PCR product was ligated into
the pGEM-T Easy vector (Promega). The vector (insert)
was cut with HpaI (10 U, Invitrogen) and a uniformly labeled
mGluRB-R/G probe was transcribed using SP6 RNA poly-
merase (30 U, invitrogen) in the buffer supplied by the
provider in the presence of [a-
32P]UTP (NEN Perkin
Elmer). The 225 nt long radioactive probe (GTTAACT-
CTTTGTATTCCTATTTTGTTGTTTGTTTATTTTTTAGT-
GGAGTCACATTCAAGACACTGTATTTGTTTGTTGTGG-
ATGTGAGTACATTGCCGTAGAATATAGAACTCCCCA)
is complementary to 118 nt of the GluR situated 698 nt down-
stream of the R/G site. The probe was puriﬁed on a 8% PAGE
plus 7 M Urea gel. The assay was performed according to the
manufacturer’s instructions (Ambion).
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Specific enrichment of targets for site-selective editing
A method was developed to detect novel site-selective A to I
editing in vivo (Figure 1). To identify ADAR2 associated
mRNAs, cell lysate from mouse brain was incubated with
anti-humanADAR2polyclonalantibody.ADAR2–RNA com-
plexes were pulled down using protein A–Sepharose beads.
The co-puriﬁed pre-mRNAs were identiﬁed by probing of
microarrays after removal of the proteins. ADAR proteins
are known to bind tightly to dsRNA of any sequence
(16,17,18). However, from previous studies we know that
ADAR2 preferentially binds single sites of selective editing
over a random sequence of completely dsRNA (15). This
might be due to a higher afﬁnity to site-selectively edited
substrates. We therefore hypothesized that this method
would speciﬁcally enrich RNA transcripts subjected to single
sites of selective editing.
ADAR2 co-immunoprecipitation using mouse brain
Using this method it is important to retain intact RNA–protein
complexes. Therefore, the cell extracts were treated with a
ribonucleoside vanadyl complex to prevent RNA degrada-
tion prior to being used as load in the IP. DNA was also
removed before further extractions to minimize non-speciﬁc
background. The speciﬁcity of the RNA–protein interaction
was optimized by washing the immunoprecipitate three times
in 1· PBS, MgCl2 (2 mM), EDTA (15 mM), NP-40 (1%) and
Tween-20 (0.5%) in presence of protease inhibitor. After SDS
treatment the speciﬁcity of the IP for ADAR2 was determined
bywesternblot(Figure 2).AnenrichmentofADAR2wasseen
when the anti-ADAR2 antibody was used in the IP compared
with precipitation using pre-immune serum.
Specific amplification of known A to I editing substrates
GluR-B is a transcript that is A to I edited site-selectively at
two sites (Q/R and R/G) within the coding sequence [reviewed
in (10)]. Although some other receptor subunits are subjected
to editing, no editing has been detected in the subunit A
(GluR-A) transcript. Another well-known substrate for A to
I editing is the transcript of the serotonin receptor 5-HT2C.
This transcript has been shown to be site-selectively edited
at several sites (A, B, C, C0 and D) (11). The speciﬁcity of
the IP for these known RNA targets was analyzed by semi-
quantitative RT–PCR (Figure 3a and b). An enrichment of
target substrates was observed in the ADAR2 IP when primers
speciﬁc for the edited sites in the GluR-B and 5-HT2C tran-
scripts were used (Figure 3a). The pre-immune IP did not
show an enrichment of target RNA. When primers speciﬁc
for GluR-A were used for ampliﬁcation no product could be
detected during the 25 cycles of PCR considered to give a
semi-quantitative product (Figure 3a). During an extended
PCR to 30 cycles a product of equal amount could be detected
in the ADAR2 and pre-immune IP (data not shown). As an
additional negative control primers speciﬁc for the mRNA of
the ribosomal phosphoprotein P0 that is not edited were used
for ampliﬁcation. No enrichment of this product could be
detected as the level of transcripts appears to be equal in
the ADAR2 and pre-immune IP elutes (Figure 3b). Editing
at the Q/R and R/G sites of the target RNAs was veriﬁed by
sequencing a population from RT–PCR (Figure 3c). Although
a mixed population ofedited and non-edited products was seen
at the R/G site the Q/R site was edited to 100%. These data are
in line with previous results showing the extent of GluR-B
editing in the mammalian brain [reviewed in (10)]. From the
sequencing analysis we can also verify that both pre-mRNA
and mRNA of the GluR-B transcript is present in the speciﬁc
IP. The GluR-B R/G site was ampliﬁed using primers speciﬁc
for the pre-mRNA while the Q/R site was ampliﬁed from
primers situated in the exons, giving a product from the
spliced mRNA. The speciﬁcity for the GluR-B transcript in
the ADAR2 IP was also veriﬁed by an RNase protection
assay detecting an RNA from the ADAR2 IP but not from
pre-immune IP (Figure 3d). Our data conﬁrm that an RNA that
Figure 1. Illustration of the IP-array method to find novel substrates for A to I
editing. Cell lysis extract was prepared from mouse brain. The extract was
immunoprecipitated using an ADAR2-specific polyclonal antibody. Target
RNA was extracted from the mRNP complexes upon protein removal. The
RNA was amplified, labeled and further hybridized to a mouse genomic oligo
array.
Figure 2. Western blot analysis using anti-human ADAR2 antibody on IP
eluates. Three mouse brains were used for ADAR2-specific and pre-
immuneserumIP,respectively.One-tenthoftheIPeluatewasusedforwestern
blot.Lane1representsthepre-immuneserumIPandlane2showstheamountof
ADAR2 in the ADAR2-specific IP.
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tissue using an anti-ADAR2 antibody in IPs.
Detection of A to I editing targets using microarray
AfterproteinremovalfromtheIPusingproteinaseKtreatment
and phenol/chloroform extraction the RNA was ampliﬁed and
labeled according to Two-Cycle Target Labeling assay (Affy-
metrix). The cRNA was hybridized to a mouse genome array
430A 2.0 (Affymetrix) to detect enriched ADAR2–RNA tar-
gets compared with IPs using pre-immune serum. Three arrays
from three independent target extractions were done. The dia-
gram in Figure 4 illustrates the extent of enrichment of the 200
genes that are signiﬁcantly enriched in all three arrays. The
GluR-B transcript was signiﬁcantly ampliﬁed in the three
arrays and is indicated in red. Other known A to I substrates
enriched in the speciﬁc IPs are speciﬁed in Table 1. Although
present, the GluR-A transcript did not show an increase in the
microarray (Table 1). This is in agreement with the presented
data from RT–PCR and RNase protection. These results indic-
ate that the method speciﬁcally ampliﬁes known selectively
edited targets that can be detected by microarray.
Figure 3. DetectionofknownsubstratesforAtoIeditingusingADAR2-specificIP.(a)Semi-quantitativeRT–PCRonGluR-BattheR/GandQ/Rsite,GluR-Aand
the serotonin receptor (5-HT2C) using radioactively labeled primers. Lane 1 shows the amplification of the R/G site from an ADAR2-specific IP, with an estimated
size of 314 bp. Lane 2 shows a product amplified from the R/G site from an IP using pre-immune serum. Lane 3 shows the amplification of the Q/R site from an
ADAR2-specificIP,withanestimatedsizeof253bp.Lane4showsproductamplificationoftheQ/RsitefromanIPusingpre-immuneserum.RT–PCRonGluR-A,
lacking sites for A to I editing, shows no detectable amplification from an ADAR2-specific IP (lane 5), or a pre-immune serum IP (lane 6). Product using total
RNAisshowninlane7andtheestimatedsizeis203bp.RT–PCRon5-HT2CshowstheamplificationfromanADAR2-specificIP(lane8),theestimatedsizeis94bp.
Lane 9 shows a product amplified from the 5-HT2C transcript from an IP using pre-immune serum. Lane M is a size marker with bands of sizes as indicated.
(b)RT–PCRontheribosomalphosphoproteinP0,lackingsitesforAtoIediting.NoenrichmentcouldbedetectedintheADAR2IP(lane1)comparedwiththepre-
immuneserum IP(lane2).The estimatedsizeis 265 bp.LaneM isa size markerwithbandsofsizesas indicated. (c) The product from theRT–PCR-specificforthe
R/GandtheQ/RsiteswereDNAsequencedtodeterminetheeditingefficiency.AttheR/GsiteaforwardprimerwasusedtogiveadualAandGpeakattheR/Gsite.
At the Q/R site a reverse primer was used so that an edited site is a C in the sequence. Edited nucleotides are indicated with an arrow in the chromatogram. (d)A n
RNase protection assay was used to confirm the enrichment of GluR-B in the presence of anti-ADAR2 antibody. A 225 nt long a-
32P-labeled probe, 118 nt
complementary downstream of the R/G site, was hybridized to RNA from an IP using pre-immune serum (lane 1) and to RNA from an IP using anti-ADAR2
antibody (lane 2).
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During the past decade several methods have been developed
to ﬁnd new ADAR substrates. By computational analysis a
vast amount of edited sites have been detected in 50- and 30-
UTRs within Alu repetitive elements that are hyper-edited at
multiple sites, but very few sites were found in coding
sequences (4–6). Although editing of Alu repeats might be
important, no function has so far been proposed.
We have developed a method to detect single sites of A to I
editing in vivo and have chosen mouse brain in our initial
experiments. The mouse genome contains fewer repetitive
elements than the human genome and lacks the Alu repeats.
By choosing ADAR2 and mouse material we can focus on
single sites of editing in coding sequences, with the potential
of creating alternative isoforms of the protein. Mouse is there-
fore a good model organism to avoid extensive A to I hyper-
editing of non-coding sequence.
Most dsRNA-binding proteins (dsRBPs) interact with the
RNA by sequence-speciﬁc structural features rather than base-
speciﬁc interactions [reviewed in (19)]. A dsRNA-binding
motif makes at least two structure-speciﬁc interactions with
the RNA double-helix. These interactions have been proven to
occur in a sequence-independent manner (20,21). However, it
has been proposed by us and others that the mismatch oppos-
ing the R/G site in GluR-B serves as a structural feature in
concert with the neighboring nucleotides to direct site-
selective editing (18,22). Further, studies on other dsRBPs
indicate that there are regions in the RNA-binding motif that
interact with RNA loop structures in the vicinity of the helical
structure (23–26). These results are in line with our previous
result indicating that the ADAR2 enzyme discriminate
between a completely dsRNA structure and a selectively
edited substrate interrupted by bulges and loops, possibly
with a slower off rate on the latter sites (15). To minimize
the background binding to dsRNA we exclude any form of
cross-linking between RNA and protein prior to the IP.
Using our approach we can collect potential ADAR sub-
strates in vivo and enrich for selectively edited sites. Using
microarray analysis as the method to detect potential targets
allows us to tolerate a certain amount of background but also
to detect products of relatively low abundance since the
material is ampliﬁed prior to the array. However it should be
noted that the microarray is limited in its detection of enriched
transcripts. Table 1 shows the enrichment of known edited
Figure4. GenesenrichedinADAR2IPcomparedwithpre-immuneserumIP.200genesweresignificantlyincreasedinallthreedifferentarrays.Themeanvaluefor
the three arrays is shown as fold increase 2
x. The GluR-B, marked in red, is ranked 25 of the 200 enriched genes.
Table 1. Enriched known editing targets and non-edited transcripts verified by
microarray
Transcript Mean (2
x-fold increase) SD
Known editing targets
GluR-B 1.37 0.23
5-HT2C 1.03 1.63
Ednrb 0.97 1.02
Igfbp 0.50 0.10
Blcap 0.33 0.12
ADAR2 0.33 1.20
Non-edited transcripts
GluR-A  0.17 0.11
ARPP P0  0.50 0.20
The following abbreviations are used: GluR-B, Glutamate receptor subunit B;
5-HT2C, serotonin receptor subtype 2C; Ednrb, Endothelin receptor type B;
Igfbp,insulin-likegrowthfactor-bindingprotein2;Blcap,bladdercancerasso-
ciated protein; ADAR2, adenosine deaminase that acts on RNA 2; GluR-A,
Glutamate receptor subunit A; ARPP P0, acidic ribosomal phophoprotein P0.
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editing show a signiﬁcant enrichment in the microarray after
the ADAR2-speciﬁc IP. However, in order to get a better
statistical value on the microarray an increased number of
independent array analyses are required. The enrichment of
edited substrates in the speciﬁc IP was veriﬁed by semi-
quantitative RT–PCR on a selective set of RNAs usingprimers
speciﬁc for the GluR-B R/G site, the GluR-B Q/R site and the
A–D sites in the 5-HT2C transcript. Using this technique we
could detect an enrichment of RNA containing all of these
sites but not for GluR-A and ARPP P0 transcripts that are not
edited. Weare thereforeconﬁdentthat edited substrates indeed
are enrichedinthe speciﬁc IP. From sequencing analysis of the
PCR products from the ampliﬁed edited transcripts we can
detect both pre-mRNA and mRNA. Detection of spliced tran-
scripts indicate that splicing has occurred subsequent to bind-
ing during the IP. Since ADAR2 has been shown to bind to
the inosine containing product with almost the same afﬁnity as
to the substrate (16), we expect that edited as well as non-
edited A to I substrates are extracted using this assay. Approx-
imately 200 genes showed a signiﬁcant increase in all three
arrays compared with microarrays based on RNA form an IP
using pre-immune serum (Figure 4). We are using computa-
tional analysis to identify the position of editing sites in the
candidate genes. When a computational search on an entire
genome is used as the sole method to identify A to I editing it
is hard to detect single sites of selective editing in the back-
ground of single nucleotide polymorphisms, sequencing errors
and mis-alignments. Since we utilize the candidates identi-
ﬁed in the experimental setup as the input the computational
search can be more general. Three main criteria are used to
get a high score on editing probability: (i) A/G mismatches
between genomic and cDNA sequence, (ii) phylogenetic con-
servation of the A/G mismatch between mammals and
(iii) inverted repeats with acceptance of mismatches and
internal loops (M. Enstero ¨, B.-M. Sjo ¨berg and M. O ¨hman,
manuscript in preparation). Each criterium is scored individu-
ally and high score candidates are veriﬁed experimentally.
This unique combination of experimental and bioinformatical
analysis has the potential to detect novel sites of selective
editing that have previously been foreseen using the methods
separately. We have detected several new candidates of A to I
editingsubstrates inmouse brainusingthisstrategy(J.Ohlson,
M. Enstero ¨, B.-M. Sjo ¨berg and M. O ¨hman, manuscript in
preparation).
Our approach has numerous applications, it can be used to
ﬁnd novel editing substrates in different tissues as well as to
identify editing discrepancies between different species. It is
also possible to apply this method on other ADAR protein
family members like ADAR1 but also ADAR3, so far without
known targets, as well as on other dsRBPs. A to I editing is an
essential event fornormalbrain function (27). Severaldiseases
with altered brain functions have been shown to have an effect
on speciﬁc sites of editing (28,29). Our method has a potential
to give a more general overview of the editing events in a
normal brain compared with a diseased one.
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